Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Bethesda North Marriott Hotel and Conference Center

02 oct 2018 7:00 a.m. - 03 oct 2018 3:00 p.m.

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

Measuring Impact in Patient-Centered Drug Development Conference

Session 4: Where and When Should We be Measuring?

Learning Objective : At the conclusion of this session, participants should be able to:
  • Identify the specific time points along the product lifecycle where patient engagement could be measured
  • Define at least three issues to consider related to the timing measurement of PE appropriately
  • Give one example of how the measurement of PE would differ depending on timing of the product lifecycle

Speaker(s)

Mathieu  Boudes, PhD

Where and When Should We be Measuring?

Mathieu Boudes, PhD

Montsouris Consilium, France

Patient Engagement Director

Bray  Patrick-Lake, MS

Measuring the Value & Impact of Patient Engagement in Clinical Trials

Bray Patrick-Lake, MS

FDA, United States

Senior Digital Health Specialist, DDH, CDRH

James  Valentine, JD, MHS

Measuring Impact in Patient Engagement: Regulatory Opportunities

James Valentine, JD, MHS

Hyman, Phelps & McNamara, PC, United States

Director

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.